Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin plus cytarabine versus cytarabine plus placebo in relapsed or refractory acute myeloid leukemia
2014-003065-15Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Idasanutlin plus cytarabine with Placebo plus cytarabine (2 arms). Primary endpoint: Overall survival. Started Dec 2015; status: terminated.
02
Drugs
idasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-003065-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003065-15.